Company Filing History:
3 out of 2,096 
1 out of 323 
Years Active: 2004-2016
Title: Javed Naim Agrewala: Innovator in Immunology
Introduction
Javed Naim Agrewala is a prominent inventor based in Chandigarh, India. He has made significant contributions to the field of immunology, holding a total of 3 patents. His work focuses on developing innovative solutions for generating long-lasting immunity against various pathogens.
Latest Patents
One of his latest patents is a synthetic immunogen that is useful for generating long-lasting immunity and protection against pathogens. This invention relates to a synthetic immunogen represented by a specific formula, which is effective against intracellular pathogens responsible for diseases such as tuberculosis, leishmaniasis, AIDS, trypanosomiasis, and malaria. The developed immunogen is designed to circumvent HLA restriction in humans and livestock, and it includes a vaccine that targets these intracellular pathogens.
Another notable patent involves the use of bipyridine compound Caerulomycin A and its derivatives as immunosuppressive agents. This invention highlights the isolated bioactive molecule's effectiveness in targeting lymphocytes, CD4T cells, CD8T cells, and B cells. The compound operates by downregulating the expression of activation markers and upregulating immunosuppressive markers, showcasing its potential in immunomodulation.
Career Highlights
Throughout his career, Javed Naim Agrewala has worked with esteemed organizations such as the Council of Scientific and Industrial Research and the University of Melbourne. His experience in these institutions has contributed to his expertise in immunology and innovation.
Collaborations
He has collaborated with notable coworkers, including Uthaman Gowthaman and David Charles Jackson, further enhancing his research and development efforts in the field.
Conclusion
Javed Naim Agrewala's contributions to immunology through his innovative patents demonstrate his commitment to advancing medical science. His work has the potential to significantly impact the development of vaccines and immunosuppressive therapies.